In light of an aging population and increasing chronic vascular disease, there is a tremendous unmet need for new medical technologies to treat potentially dangerous chronic venous insufficiency (CVI) and blood clots, according to a Scientia Advisors review of the vascular device market. Both the CVI and the thrombosis segments present significant opportunities for medical device innovators.

 “Most vascular devices currently on the market treat only symptoms, have low patient compliance or are highly invasive, with significant side effects or risks," said Arshad Ahmed, a partner at Scientia Advisors. “There are great needs for novel methods of compression and ablation to treat varicose veins and for minimally invasive catheter technologies that can safely and easily do away with potentially deadly blood clots.”

With most major cardiovascular players focused elsewhere, smaller companies have an important presence in the venous sub-markets. Hence, emerging companies can impact what is currently a fragmented marketplace that Scientia feels will offer larger, anchor companies an opportunity to acquire or license. “However, companies seeking to enter these venous fields should recognize that innovative, effective technologies are not enough to ensure success. Sophisticated sales and marketing, physician education, understanding of reimbursement, and attention to health economics and outcomes are crucial to product viability," adds Ahmed.

Key findings of the report include:

  • The $5B vascular device market, a relatively small piece of the $300B medical device market, has shown a sustained compound annual growth rate of 10 percent since 2007—driven largely by older, more obese and diabetic populations. 
  • As a result of recent acquisitions, medical device company Covidien’s $1B vascular group accounts for 22 percent of the market.
  • With smaller companies engaging in acquisitions and large firms limiting their activity to licensing agreements, the market is on the verge of consolidating.
  • Chronic venous insufficiency, which ranges in severity from aesthetically displeasing spider veins to large, open-wound venous ulcers, affects 2-7 percent of the U.S. population — including approximately half of women over age 50.
  • CVI is most commonly treated with compression therapy, however, compression does not treat underlying causes of CVI.
  • Promising new therapies include dynamic compression, in which a pumping device applies intermittent pressure and endovenous ablation, in which faulty superficial veins are collapsed using heat from a laser or radiofrequency energy, delivered via catheter.
  • Dynamic compression could see considerable growth if clinical trials show it works better than “static” methods.
  • The endovenous ablation market is growing rapidly and may displace invasive surgical methods such as vein stripping and phlebectomy.
  • Thrombosis, or blood clot formation, can lead to embolism, a condition in which a clot moving through the vascular system gets lodged in a vessel. Every year, two million Americans are affected by deep vein thrombosis (DVT). Some 6 percent of those with DVT die within one month of diagnosis, primarily due to  pulmonary (lung) embolism.
  • Oral anti-thrombotics, which cost $2,000 - $3,000 per patient per year, do not prevent thrombosis recurrence and can cause increased bleeding. Intravenous injection of anti-thrombotics substantially increases the risk of major hemorrhage and does not fully recanalize the vein in 66 percent of patients.
  • Promising new therapies include novel catheter technologies for localized removal of thrombi, for which FDA approval was first granted in 2006.

The report is available for download at no charge at